Rajiv Dhand

Dr. Rajiv Dhand


Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2011 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
BLB.L. Laube
B.L. Laube
HJH.M. Janssens
H.M. Janssens
FJF.H.C. de Jongh
F.H.C. de Jongh
SDS.G. Devadason
S.G. Devadason
RDRajiv Dhand
Rajiv Dhand
HCH. Chrystyn
H. Chrystyn
A collaboration of multidisciplinary experts on the delivery of pharmaceutical aerosols was facilitated by the European Respiratory Society (ERS) and the International Society for Aerosols in Medicine (ISAM), in order to draw up a consensus statement with clear, up-to-date recommendations that enable the pulmonary physician to choose the type of aerosol delivery device that is most suitable for their patient. The focus of the consensus statement is the patient-use aspect of the aerosol delivery devices that are currently available.The subject was divided into different topics, which were in turn assigned to at least two experts. The authors searched the literature according to their own strategies, with no central literature review being performed. To achieve consensus, draft reports and recommendations were reviewed and voted on by the entire panel.Specific recommendations for use of the devices can be found throughout the statement. Healthcare providers should ensure that their patients can and will use these devices correctly. This requires that the clinician: is aware of the devices that are currently available to deliver the prescribed drugs; knows the various techniques that are appropriate for each device; is able to evaluate the patient's inhalation technique to be sure they are using the devices properly; and ensures that the inhalation method is appropriate for each patient.

1 January 2005 in Chest
Verified
Journal Article
Closed access
PDF file
MDMyrna Dolovich
Myrna Dolovich
RARichard C. Ahrens
Richard C. Ahrens
DHDean R. Hess
Dean R. Hess
PAPaula Anderson
Paula Anderson
RDRajiv Dhand
Rajiv Dhand
GGGordon Guyatt
Gordon Guyatt

1 March 2011 in The Lancet
Verified
Journal Article
Closed access
MDMyrna Dolovich
Myrna Dolovich
RDRajiv Dhand
Rajiv Dhand

1 September 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
RDRajiv Dhand
Rajiv Dhand
JLJie Li
Jie Li
Coughs and sneezes disperse a large number of droplets of varying size into the environment, and they transmit respiratory viral infections by direct or indirect physical contact, by droplets or inhalation of fine particulate droplet nuclei. Larger droplets in the cloud produced by coughing and sneezing settle quickly, and the force with which they are expelled determines how far they are dispersed. The respiratory droplets evaporate to form smaller droplet nuclei that carry infectious agents, remain suspended in air, and susceptible individuals farther away from the source could inhale them. The particle size distribution within the multi-phase cloud produced by coughs/sneezes changes with time and distance from the source depending on several environmental factors. After inhalation, larger respiratory droplets are filtered by the nose or deposit in the oropharynx, whereas smaller droplet nuclei are carried by the airstream into the lungs where their site of deposition depends on their mass, size and shape and is governed by various mechanisms. Airborne particles could also be produced by various aerosol generating procedures, such as suctioning or tracheal intubation, and by aerosol generators, especially jet nebulizers. Prevention of respiratory viral infections depends upon whether they are carried in respiratory droplets or as fine droplet nuclei (airborne or aerosol transmission). The SARS-CoV-2 virus that causes COVID-19 is mainly transmitted by respiratory droplets or by contact. Airborne transmission of this virus has not been established, but is possible under special circumstances. Appropriate protective measures are necessary to prevent transmission of SARS-CoV-2 virus in various settings. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1 July 1997 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
RDRajiv Dhand
Rajiv Dhand
MTMartin J. Tobin
Martin J. Tobin

1 March 2008 in Journal of Aerosol Medicine and Pulmonary Drug Delivery
Verified
Journal Article
Closed access
RDRajiv Dhand
Rajiv Dhand
Pressurized metered-dose inhalers (pMDIs) and nebulizers are routinely employed for aerosol delivery in mechanically ventilated patients. A significant proportion of the aerosol deposits in the ventilator circuit and artificial airway, thereby reducing the inhaled drug mass. Factors influencing aerosol delivery during mechanical ventilation differ from those in spontaneously breathing patients. The English language literature on aerosol delivery during mechanical ventilation was reviewed. Marked variations in the efficiency of drug delivery with pMDIs and nebulizers occur due to differences in the technique of administration. Careful attention to five factors, viz., the aerosol generator, aerosol particle size, conditions in the ventilator circuit, artificial airway, and ventilator parameters, is necessary to optimize aerosol delivery during mechanical ventilation. Factors influencing drug delivery during NPPV are not well understood, and the efficiency of aerosol delivery in this setting is lower than that during invasive mechanical ventilaiton. With an optimal technique of administration the efficiency of aerosol delivery during mechanical ventilation is similar to that achieved during spontaneous breathing. Further research is needed to optimize aerosol delivery during NPPV.